Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Possinger

Showing results (101-110 of 166) with videos related to

Pageof 17
Sort By:
British Journal of Cancer|June 5, 2003
Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancerC Langelotz, P Schmid, C Jakob, et al.
Breast Cancer Research and Treatment|September 25, 2003
Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patientsD Lüftner, A Jung, P Schmid, et al.
Investigational New Drugs|December 16, 1998
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I studyD Lüftner, B Flath, C Akrivakis, et al.
Annals of Hematology|June 2, 2000
An unusual case of leukemic non-Hodgkin's lymphoma with blastic transformationE Späth-Schwalbe, B Flath, O Kaufmann, et al.
Deutsche Medizinische Wochenschrift (1946)|May 18, 1999
[Primary cerebral highly-malignant B-cell lymphoma of the Burkitt type]E Späth-Schwalbe, I Genvresse, H Stein, et al.
Onkologie|October 1, 1986
Phase-II studies of 1,2,4-triglycidylurazol (TGU) in solid tumors. Phase-II Study Group of the Association of Medical Oncology of the German Cancer SocietyW Queisser, H E Wander, K Possinger, et al.
Anti-Cancer Drugs|July 8, 2000
Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I studyK Akrivakis, P Schmid, B Flath, et al.
Anti-Cancer Drugs|October 3, 1999
Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancerP Schmid, K Akrivakis, B Flath, et al.
Anti-Cancer Drugs|May 4, 2001
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative studyI Genvresse, C Lange, J Schanz, et al.
Breast Cancer Research and Treatment|November 6, 2012
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancerC F Jehn, B Flath, A Strux, et al.
Pageof 17

Showing results (101-110 of 166) with videos related to

Sort By:
Pageof 17
British Journal of Cancer|June 5, 2003
Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancerC Langelotz, P Schmid, C Jakob, et al.
Breast Cancer Research and Treatment|September 25, 2003
Upregulation of HER-2/neu by ovarian ablation: results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patientsD Lüftner, A Jung, P Schmid, et al.
Investigational New Drugs|December 16, 1998
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I studyD Lüftner, B Flath, C Akrivakis, et al.
Annals of Hematology|June 2, 2000
An unusual case of leukemic non-Hodgkin's lymphoma with blastic transformationE Späth-Schwalbe, B Flath, O Kaufmann, et al.
Deutsche Medizinische Wochenschrift (1946)|May 18, 1999
[Primary cerebral highly-malignant B-cell lymphoma of the Burkitt type]E Späth-Schwalbe, I Genvresse, H Stein, et al.
Onkologie|October 1, 1986
Phase-II studies of 1,2,4-triglycidylurazol (TGU) in solid tumors. Phase-II Study Group of the Association of Medical Oncology of the German Cancer SocietyW Queisser, H E Wander, K Possinger, et al.
Anti-Cancer Drugs|July 8, 2000
Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I studyK Akrivakis, P Schmid, B Flath, et al.
Anti-Cancer Drugs|October 3, 1999
Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancerP Schmid, K Akrivakis, B Flath, et al.
Anti-Cancer Drugs|May 4, 2001
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative studyI Genvresse, C Lange, J Schanz, et al.
Breast Cancer Research and Treatment|November 6, 2012
Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancerC F Jehn, B Flath, A Strux, et al.
Pageof 17